Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2016, Article ID 2389038, 4 pages
http://dx.doi.org/10.1155/2016/2389038
Case Report

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib

1Division of Infectious Diseases, Department of Medicine, University of Colorado, Denver, CO, USA
2Division of Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
3University of Birmingham Medical School, Edgbaston, Birmingham, UK
4Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
5Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

Received 8 August 2016; Revised 3 October 2016; Accepted 4 October 2016

Academic Editor: Eduardo Arellano-Rodrigo

Copyright © 2016 Maheen Z. Abidi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. A. Mesa, J. Gotlib, V. Gupta et al., “Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial,” Journal of Clinical Oncology, vol. 31, no. 10, pp. 1285–1292, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Parampalli Yajnanarayana, T. Stübig, I. Cornez et al., “JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms,” British Journal of Haematology, vol. 169, no. 6, pp. 824–833, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Schönberg, J. Rudolph, M. Vonnahme et al., “JAK inhibition impairs NK cell function in myeloproliferative neoplasms,” Cancer Research, vol. 75, no. 11, pp. 2187–2199, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Verstovsek, H. Kantarjian, R. A. Mesa et al., “Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis,” The New England Journal of Medicine, vol. 363, no. 12, pp. 1117–1127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Branco, D. Metsu, M. Dutertre et al., “Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib,” Annals of Hematology, vol. 95, no. 7, pp. 1207–1209, 2016. View at Publisher · View at Google Scholar
  6. Y.-H. Chen, C.-H. Lee, and S.-N. Pei, “Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis,” Leukemia & Lymphoma, vol. 56, no. 5, pp. 1528–1529, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Colomba, R. Rubino, L. Siracusa et al., “Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report,” BMC Research Notes, vol. 5, article 552, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. R. A. Goldberg, E. Reichel, and L. J. Oshry, “Bilateral toxoplasmosis retinitis associated with ruxolitinib,” New England Journal of Medicine, vol. 369, no. 7, pp. 681–683, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. R. K. Hopman, S. J. Lawrence, and S. T. Oh, “Disseminated tuberculosis associated with ruxolitinib,” Leukemia, vol. 28, no. 8, pp. 1750–1751, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Keizer, R. Gerritsen, Y. Jauw, J. Janssen, B. Koopman, and P. Bresser, “Fatal tuberculosis during treatment with ruxolitinib,” Nederlands Tijdschrift voor Geneeskunde, vol. 159, no. 22, article A8650, 2015. View at Google Scholar · View at Scopus
  11. F. Palandri, N. Polverelli, L. Catani, and N. Vianelli, “Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge,” Annals of Hematology, vol. 94, no. 3, pp. 519–520, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Shamil, D. Cunningham, B. L. Wong, and P. Jani, “Ruxolitinib associated tuberculosis presenting as a neck lump,” Case Reports in Infectious Diseases, vol. 2015, Article ID 284168, 3 pages, 2015. View at Publisher · View at Google Scholar
  13. J. von Hofsten, M. Johnsson Forsberg, and M. Zetterberg, “Cytomegalovirus retinitis in a patient who received ruxolitinib,” The New England Journal of Medicine, vol. 374, no. 3, pp. 296–297, 2016. View at Publisher · View at Google Scholar
  14. R. Wathes, S. Moule, and D. Milojkovic, “Progressive multifocal leukoencephalopathy associated with ruxolitinib,” The New England Journal of Medicine, vol. 369, no. 2, pp. 197–198, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. N. G. Wysham, D. R. Sullivan, and G. Allada, “An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor,” Chest, vol. 143, no. 5, pp. 1478–1479, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Thiele, H. M. Kvasnicka, F. Facchetti, V. Franco, J. Van Der Walt, and A. Orazi, “European consensus on grading bone marrow fibrosis and assessment of cellularity,” Haematologica, vol. 90, no. 8, pp. 1128–1132, 2005. View at Google Scholar · View at Scopus
  17. D. P. McLornan, A. A. Khan, and C. N. Harrison, “Immunological consequences of JAK inhibition: friend or foe?” Current Hematologic Malignancy Reports, vol. 10, no. 4, pp. 370–379, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. W. G. Dixon, K. L. Hyrich, K. D. Watson et al., “Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR),” Annals of the Rheumatic Diseases, vol. 69, no. 3, pp. 522–528, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Nahid, S. E. Dorman, N. Alipanah et al., “Official American Thoracic Society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis,” Clinical Infectious Diseases, vol. 63, no. 7, pp. e147–e195, 2016. View at Publisher · View at Google Scholar